Who is eligible for clinical trial NCT05607420?

Participants must meet the protocol's inclusion criteria for B-cell Non-Hodgkin Lymphoma (B-NHL). The stated age range is 18 Years to 80 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT05607420 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma (NCT05607420)

Open-label Dose-finding and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART20x22 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL)

🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Cellectis S.A.

🩺 Plain-English Summary (8th-Grade Level)

First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22 administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to evaluate the safety and clinical activity of UCART20x22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (11 items) and avoid the listed exclusions (22 items).

Location: The University of Chicago Medical Center (UCMC) — Chicago, Illinois

Age range: 18 Years to 80 Years

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Prior use of an investigational product (except for cell or gene therapies and MoAbs) within 5 half-lives or within 14 days, whichever is shorter, prior to start of LD regimen
Previous approved therapy including chemotherapy, biologic (except MoAbs), or targeted therapy for R/R B-NHL with 5 half-lives or within 14 days, whichever is shorter, prior to start of the LD regimen
\> 4 lines of therapy R/R B-NHL prior to start of the LD regimen.
Prior MoAb therapy (approved or investigational) within 30 days prior to start of LD
Prior systemic immunostimulatory agent within 3 half-lives prior to start of the LD regimen
Prior cell or gene therapy (approved or investigational) within 6 months of the start of LD
Prior cell or gene therapy (approved or investigational) targeting both CD20 and CD22
Autologous HSCT infusion within 6 weeks of the start of LD
Allogeneic HSCT within 3 months of the start of LD, or donor lymphocyte infusion within 6 weeks of the start of LD
Active acute or chronic graft versus host disease (GvHD). Subjects should be off all immunosuppressive therapies for at least 6 weeks prior to start of LD
Radiotherapy within 8 weeks (except for palliative radiotherapy for specific on-target lesions) (prior to start of LD regimen)

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (10 Sites)

The University of Chicago Medical Center (UCMC) — Chicago, Illinois
Harvard Medical School - Massachusetts General Hospital — Boston, Massachusetts
Rutgers Cancer Institute of New Jersey (CINJ) - New Brunswick — New Brunswick, New Jersey
Sarah Cannon - St. David South Austin Medical Center — Austin, Texas
Hospices Civils de Lyon (HCL) - Centre Hospitalier Lyon-Sud — Pierre-Bénite, Auvergne Rhone Alpe
Centre Hospitalier Universitaire de Montpellier (CHU Montpellier) - Hopital Saint-Eloi — Montpellier, Occitanie
Centre Hospitalier Universitaire de Nantes (CHU de Nantes)-Hotel-Dieu — Nantes,
Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Saint-Louis - Centre Integre en Cancerologie — Paris, Île-de-France Region
Universidad de Navarra - Clinica Universidad de Navarra (CUN) - Pamplona — Pamplona, Navarre
Hospital Universitario Virgen del Rocio (HUVR) - Instituto de Biomedicina de Sevilla (IBIS) — Seville,

📞 Contact the Study Coordinator

Phone: (917) 580-1088

Email: clinicaltrials@cellectis.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗